CA3097443A1 - Proteines de fusion contenant des anticorps anti-cd47 et des cytokines - Google Patents
Proteines de fusion contenant des anticorps anti-cd47 et des cytokines Download PDFInfo
- Publication number
- CA3097443A1 CA3097443A1 CA3097443A CA3097443A CA3097443A1 CA 3097443 A1 CA3097443 A1 CA 3097443A1 CA 3097443 A CA3097443 A CA 3097443A CA 3097443 A CA3097443 A CA 3097443A CA 3097443 A1 CA3097443 A1 CA 3097443A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- gmcsf
- fusion protein
- antibody
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des protéines de fusion contenant des cytokines et de nouveaux anticorps anti-CD47 ou des fragments immunologiquement actifs de ceux-ci, ainsi des compositions pharmaceutiques contenant de telles protéines de fusion qui peuvent être utilisées pour le traitement de maladies à médiation par CD47 ou l'inhibition de la phagocytose ou de l'agrégation plaquettaire. Ces protéines fusionnées ont une faible immunogénicité chez l'homme et provoquent un niveau faible ou nul de déplétion des globules rouges ou d'hémagglutination.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/114975 WO2019091473A1 (fr) | 2017-11-10 | 2018-11-12 | Protéines de fusion contenant des anticorps anti-cd47 et des cytokines |
CNPCT/CN2018/114975 | 2018-11-12 | ||
PCT/CN2019/085096 WO2020098232A1 (fr) | 2017-11-10 | 2019-04-30 | Protéines de fusion contenant des anticorps anti-cd47 et des cytokines |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3097443A1 true CA3097443A1 (fr) | 2020-05-22 |
Family
ID=68815606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3097443A Pending CA3097443A1 (fr) | 2018-11-12 | 2019-04-30 | Proteines de fusion contenant des anticorps anti-cd47 et des cytokines |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110582515A (fr) |
CA (1) | CA3097443A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023523977A (ja) * | 2020-04-30 | 2023-06-08 | アイ-マブ バイオファーマ ユーエス リミテッド | 抗cd47抗体を含む医薬組成物 |
TW202229861A (zh) * | 2020-10-14 | 2022-08-01 | 中國大陸商天境生物科技(上海)有限公司 | 藉由治療性抗cd47抗體於輸血前檢驗中減輕干擾之方法 |
CN116348601A (zh) * | 2020-10-14 | 2023-06-27 | 天境生物科技(上海)有限公司 | 新型抗cd47抗体及其用途 |
WO2022100694A1 (fr) | 2020-11-12 | 2022-05-19 | 迈威(上海)生物科技股份有限公司 | Anticorps et son procédé de préparation |
CN113303285B (zh) * | 2021-07-29 | 2021-11-23 | 澎立生物医药技术(上海)有限公司 | 一种血小板特异抗原诱导猴itp模型的构建方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1135529A (zh) * | 1996-02-14 | 1996-11-13 | 中国预防医学科学院病毒学研究所 | 一种具有较高生物学活性的gm-csf突变体及制法 |
WO2001068141A2 (fr) * | 2000-03-17 | 2001-09-20 | Maxygen Aps | Dispersions de conjugues polypeptidiques |
AU2002212108A1 (en) * | 2000-11-02 | 2002-05-15 | Maxygen Aps | Single-chain multimeric polypeptides |
JP2009537145A (ja) * | 2006-05-15 | 2009-10-29 | バイラル ロジック システムズ テクノロジー コーポレーション | 免疫学的疾患および障害を治療するためのcd47と関連した組成物および方法 |
US8142791B2 (en) * | 2006-11-27 | 2012-03-27 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Multi-modal cancer therapy using viral hitch-hiking |
CN100579989C (zh) * | 2007-04-02 | 2010-01-13 | 中国疾病预防控制中心病毒病预防控制所 | 白喉毒素与gm-csf的融合蛋白及其编码基因与应用 |
CN100579988C (zh) * | 2007-04-02 | 2010-01-13 | 中国疾病预防控制中心病毒病预防控制所 | 白喉毒素与gm-csf突变体的融合蛋白及其编码基因与应用 |
EP2344203A2 (fr) * | 2008-09-19 | 2011-07-20 | Maxygen, Inc. | Procédé de traitement d'une neutropénie induite par rayonnement, par l administration d'une variante de facteur stimulant une colonie de granulocytes multipégylés (g-csf) |
JP5969458B2 (ja) * | 2010-04-09 | 2016-08-17 | アルブミディクス アクティーゼルスカブ | アルブミン誘導体及び変異体 |
TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
US20140050720A1 (en) * | 2012-01-09 | 2014-02-20 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
US9388239B2 (en) * | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
CN109312304A (zh) * | 2016-04-20 | 2019-02-05 | 弗雷德哈钦森癌症研究中心 | 免疫调节性il2r融合蛋白及其用途 |
CN107840885B (zh) * | 2016-09-19 | 2020-11-10 | 天境生物科技(上海)有限公司 | Gm-csf抗体及其用途 |
KR20220104298A (ko) * | 2016-10-20 | 2022-07-26 | 아이-맵 바이오파마 유에스 리미티드 | 새로운 cd47 단일클론 항체 및 그 용도 |
EP3541941A4 (fr) * | 2017-11-10 | 2019-12-25 | I-Mab Biopharma US Limited | Protéines de fusion contenant des anticorps anti-cd47 et des cytokines |
SG11202104301SA (en) * | 2018-10-31 | 2021-05-28 | I Mab Biopharma Us Ltd | Novel cd47 antibodies and methods of using same |
-
2019
- 2019-04-30 CN CN201980001915.5A patent/CN110582515A/zh active Pending
- 2019-04-30 CA CA3097443A patent/CA3097443A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110582515A (zh) | 2019-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210054093A1 (en) | Novel CD47 Monoclonal Antibodies and Uses Thereof | |
ES2796378T3 (es) | Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos | |
US20210269522A1 (en) | Novel CD47 Antibodies and Methods of Using Same | |
US20200407441A1 (en) | Fusion Proteins Containing CD48 Antibodies and Cytokines | |
CA3097443A1 (fr) | Proteines de fusion contenant des anticorps anti-cd47 et des cytokines | |
EA041310B1 (ru) | Новые моноклональные антитела к cd47 и их использование |